Harmony Biosciences Holdings
$ 32.08
0.34%
23 Apr - close price
- Market Cap 1,856,386,000 USD
- Current Price $ 32.08
- High / Low $ 32.57 / 31.66
- Stock P/E 11.84
- Book Value 15.07
- EPS 2.71
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.21 %
- 52 Week High 40.87
- 52 Week Low 25.52
About
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Analyst Target Price
$42.91
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-27 | 2025-08-05 | 2025-04-28 | 2025-02-20 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-22 | 2023-10-31 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 0.57 | 1.08 | 0.68 | 0.7785 | 1.08 | 0.79 | 0.2 | 0.67 | 0.45 | 0.75 | 0.56 | 0.66 |
| Estimated EPS | 0.86 | 0.8149 | 0.72 | 0.9136 | 0.8171 | 0.67 | -0.06 | 0.6 | 0.48 | 0.65 | 0.63 | 0.47 |
| Surprise | -0.29 | 0.2651 | -0.04 | -0.1351 | 0.2629 | 0.12 | 0.26 | 0.07 | -0.03 | 0.1 | -0.07 | 0.19 |
| Surprise Percentage | -33.7209% | 32.5316% | -5.5556% | -14.7877% | 32.1748% | 17.9104% | 433.3333% | 11.6667% | -6.25% | 15.3846% | -11.1111% | 40.4255% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.76 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRMY
2026-04-23 18:09:21
This article reports that Harmony Biosciences received FDA label expansion for its drug Wakix (pitolisant) to treat excessive daytime sleepiness and cataplexy in children aged six and older with narcolepsy. This approval is based on positive results from the Phase 3 HARMONY trial, which demonstrated a significant reduction in weekly rates of these symptoms compared to placebo. Wakix is now positioned as a new treatment option for pediatric narcolepsy patients.
2026-04-23 12:09:21
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced it will report its first quarter 2026 financial results on May 7, 2026, before the U.S. financial markets open. The company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the results. Harmony Biosciences is a pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases.
2026-04-23 08:05:00
Harmony Biosciences Holdings, Inc. will report its first quarter 2026 financial results on Thursday, May 7, 2026, before the U.S. financial markets open. The company will host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the results. Harmony Biosciences focuses on developing innovative therapies for patients with rare neurological diseases.
2026-04-23 05:40:52
Harmony Biosciences announced that the FDA has approved a label expansion for its drug Wakix (pitolisant) to include the treatment of excessive daytime sleepiness or cataplexy in pediatric patients aged 6 years and older with narcolepsy. This approval makes Wakix the first and only non-scheduled treatment approved for pediatric narcolepsy, addressing a significant unmet medical need for children suffering from this chronic neurological condition. The decision was based on positive results from a phase 3 clinical trial.
2026-04-22 14:39:36
Oppenheimer raised its price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) shares to $72 from $62, maintaining an Outperform rating due to the company's patent strength and settlements with generic filers. The firm anticipates Wakix's loss of exclusivity extending into 2030 and significant progress in pediatric exclusivity. Despite this, other analysts (UBS and Truist Securities) have issued lower price targets citing potential generic competition by 2029 or 2030.
2026-04-22 14:39:35
Harmony Biosciences (HRMY) stock rose 9.7% after the appointment of Glenn Reicin as CFO and the reiteration of its 2026 net product revenue guidance of US$1.00 billion to US$1.04 billion. While this signals continuity and focuses on execution, capital discipline, and growth, the article notes that the core investment narrative, including concentration risk around WAKIX and pipeline risk, remains largely unchanged. The new CFO and reaffirmed guidance will serve as benchmarks for evaluating future capital allocation and business development, yet some analysts hold a more bullish long-term outlook for the company.
